IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 026083/0138

In re patent application of

Group Art Unit: 1616

Hans Ulrich Stilz et al.

Serial No. 08/971,960

Examiner: S. Qazi

Filed: November 17, 1997

5-MEMBERED RING HETEROCYCLES AS INHIBITORS OF LEUCOCY

ADHESION AND AS VLA-4 ANTAGONISTS

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

For:

In response to the restriction requirement mailed Dec. 22, 1999, Applicants provisionally elect with traverse Group II (claims 21-24 and 39-103) where benzodioxarane (five membered) is the only permitted hetero ring in addition to imidazole, which is understood by applicants to cover compounds in which imidazole is the only hetero ring and compounds in which benzodioxarane (five membered) is the only hetero ring in addition to imidazole. Applicants further elect the species of example 53 (page 75 of the present specification) for prosecution on the merits within Group II.

Although it appears to applicants that Group II as defined in the Office Action does cover compounds such as that in example 53 (where the only hetero ring is imidazole), to the extent that the Examiner did not intend such a definition, then applicants request the Examiner to draw the examinable subgenus around the species of example 53 (as indicated on page 3, third paragraph, of the Office Action).

Serial No. 08/971,960

Applicants understand that "benzodioxarane (five membered)" refers to a moiety having the following structure:

In view of the above amendments and remarks, favorable reconsideration and allowance of the application are requested. In the event that any issues remain, the Examiner is invited to telephone the undersigned with any proposal that would further expedite prosecution.

Respectfully submitted,

Date

Stephen B. Maebius Registration No. 35,264

FOLEY & LARDNER 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109 Telephone: (202) 672-5569

Feb. 16,2000